Inpharma 1244 - 1 Jul 2000

■ The taxane IDN-5109* shows antitumour activityafter IV or oral administration in athymic nude micebearing human tumour cells, report researchers fromItaly. In this study, groups of such mice received IV ororal IDN-5109 or paclitaxel [‘Taxol’]. In mice bearingcells from a colon carcinoma, cisplatin-resistantovarian carcinoma or glioblastoma tumour line, theantitumour efficacy of oral IDN-5109 was lower thanthat of IV IDN-5109 at the same dosage, but higherthan that of IV paclitaxel. In mice bearing cells from amammary carcinoma tumour line which is highlyresponsive to IV taxanes, oral IDN-5109 90 mg/kgevery 4 days for 4 doses resulted in a 100% cure rate,whereas no antitumour activity was seen with thesame dosage of oral paclitaxel.* Indena; preclinical

Polizzi D, et al. Oral efficacy and bioavailability of a novel taxane. Clinicalcancer research: an official journal of the American Association for CancerResearch 6: 2070-2074, May 2000 800831338

1

Inpharma 1 Jul 2000 No. 12441173-8324/10/1244-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved